Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) has provided an update.
Zymeworks Inc. said it will report its fourth quarter and full year 2025 financial results before markets open on March 2, 2026, and will host a conference call and webcast that morning to review the numbers and provide a broader corporate update. The timing signals an opportunity for investors and partners to assess the performance of its asset and royalty aggregation strategy, as well as progress across its pipeline of licensed products and emerging biotherapeutic candidates.
The upcoming results and management commentary will be closely watched for indications of how cash flows from key programs such as Ziihera and other partnered assets are supporting Zymeworks’ investment in next-generation antibody-based therapeutics. Given its reliance on strategic collaborations and a growing royalty base, the update may shed light on the company’s competitive position in oncology and immunology, and on how effectively it is leveraging its technology platforms and partnerships to drive long-term growth.
The most recent analyst rating on (ZYME) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back mainly by weak profitability and negative operating cash flow, with additional pressure from bearish/oversold technical signals. Offsetting these, the latest earnings call was meaningfully constructive—highlighting milestone-driven revenue growth, promising clinical updates, and a multi-year cash runway—supporting a more neutral overall outcome.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disorders. Its asset and royalty aggregation strategy centers on optimizing future cash flows from licensed products such as Ziihera (zanidatamab-hrii) and pasritamig, while building additional healthcare assets to fund early-stage innovation in antibody drug conjugates and multispecific antibody therapeutics.
Average Trading Volume: 1,110,243
Technical Sentiment Signal: Buy
Current Market Cap: $1.71B
See more data about ZYME stock on TipRanks’ Stock Analysis page.